Full-Time

Research Associate

Biology

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function improvement

Biotechnology
Healthcare

Compensation Overview

$48.21 - $58.46Hourly

Mid

San Bruno, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • BS/MS in Biology, Physiology, Pharmacology, or a related field with 3-5 years of relevant research experience.
  • Basic data management skills and the ability to present data clearly and effectively is required.
  • Prior experience with a range of biochemical, cellular, and molecular biology techniques (e.g., cell culture, western blots, qPCR, immunohistochemistry, enzyme assays, etc) is required.
  • Experience in cell-based models (e.g. primary myocyte isolations, iPSC culture and differentiation, and/or 3D models) is preferred.
  • Experience and knowledge in muscle mechanics and methods to assess contractility is highly desired.
  • Proficiency in basic rodent handling and dosing techniques is highly desired.
  • Experience in a pharmaceutical/biotechnology environment is a plus.
  • Team-oriented, detail-oriented, proactive.
  • Excellent oral and written communication skills are essential.
Responsibilities
  • Conduct and manage a wide range of cell-based or biochemical assays to advance our preclinical drug discovery programs in cardiac muscle biology.
  • Measure biomarkers of disease progression and compound efficacy.
  • Oversee animal colony cohorts for ex vivo studies, ensuring adherence to ethical guidelines and protocols.
  • Document methodology and experimental results, manage data, and prepare and present research findings.
  • Collaborate closely with other team members to build understanding of disease pathogenesis and the mechanism of action of drug candidates.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma for R&D and commercial launches.
  • Positive Phase III results for aficamten in treating obstructive hypertrophic cardiomyopathy.
  • FDA initiatives may expedite approval for Cytokinetics' rare disease treatments.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos in hypertrophic cardiomyopathy market.
  • Dependence on successful clinical trials like SEQUOIA-HCM for financial stability.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets rare conditions like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics has a robust pipeline, including drugs like omecamtiv mecarbil and aficamten.

Help us improve and share your feedback! Did you find this helpful?